409 related articles for article (PubMed ID: 31958355)
1. Enablers and barriers for the provision of community-based HCV treatment: A case study of a real-world practice.
Pourmarzi D; Smirnov A; Hall L; Thompson H; FitzGerald G; Rahman T
J Viral Hepat; 2020 May; 27(5):484-496. PubMed ID: 31958355
[TBL] [Abstract][Full Text] [Related]
2. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of a tertiary-based innovative approach to engage primary care providers in provision of hepatitis C treatment in community settings.
Pourmarzi D; Thompson H; Thomas JA; Hall L; Smirnov A; FitzGerald G; Rahman T
BMC Public Health; 2019 Oct; 19(1):1335. PubMed ID: 31640625
[TBL] [Abstract][Full Text] [Related]
4. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
5. Framework for community-based models for treating hepatitis C virus.
Pourmarzi D; Hall L; Smirnov A; Hepworth J; Rahman T; FitzGerald G
Aust Health Rev; 2020 Jun; 44(3):459-469. PubMed ID: 31671288
[TBL] [Abstract][Full Text] [Related]
6. Prescribing direct-acting antivirals to treat hepatitis C virus in a general practice setting in Australia: 'so why not do it'?
Heard E; Massi L; Smirnov A; Selvey LA
Intern Med J; 2020 Sep; 50(9):1053-1058. PubMed ID: 31589351
[TBL] [Abstract][Full Text] [Related]
7. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia.
Heard E; Smirnov A; Massi L; Selvey LA
J Subst Abuse Treat; 2021 Aug; 127():108460. PubMed ID: 34134878
[TBL] [Abstract][Full Text] [Related]
8. Provider-related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis.
Whiteley D; Speakman E; Elliott L; Davidson K; Hamilton E; Jarvis H; Quinn M; Flowers P
J Viral Hepat; 2021 Mar; 28(3):528-537. PubMed ID: 33215781
[TBL] [Abstract][Full Text] [Related]
9. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
[TBL] [Abstract][Full Text] [Related]
10. Primary Care Providers' Use of Genetic Services in the Southeast United States: Barriers, Facilitators, and Strategies.
Seibel E; Gunn G; Ali N; Jordan E; Kenneson A
J Prim Care Community Health; 2022; 13():21501319221134752. PubMed ID: 36345220
[TBL] [Abstract][Full Text] [Related]
11. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.
Amoako A; Ortiz-Paredes D; Engler K; Lebouché B; Klein MB
Int J Drug Policy; 2021 Oct; 96():103247. PubMed ID: 33853727
[TBL] [Abstract][Full Text] [Related]
12. A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South.
Sherbuk JE; Tabackman A; McManus KA; Kemp Knick T; Schexnayder J; Flickinger TE; Dillingham R
Harm Reduct J; 2020 Sep; 17(1):64. PubMed ID: 32948189
[TBL] [Abstract][Full Text] [Related]
13. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
14. "I want to feel young again": experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada.
Jacob J; Goodyear T; Coulaud PJ; Hoong P; Ti L; Knight R
Can J Public Health; 2021 Oct; 112(5):947-956. PubMed ID: 34115340
[TBL] [Abstract][Full Text] [Related]
15. Improving access to care for people who inject drugs: Qualitative evaluation of project ITTREAT-An integrated community hepatitis C service.
Phillips C; Schulkind J; O'Sullivan M; Edelman N; Smith HE; Verma S; Jones CJ
J Viral Hepat; 2020 Feb; 27(2):176-187. PubMed ID: 31566851
[TBL] [Abstract][Full Text] [Related]
16. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
17. Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence.
Rogal SS; McCarthy R; Reid A; Rodriguez KL; Calgaro L; Patel K; Daley M; Jonassaint NL; Zickmund SL
Dig Dis Sci; 2017 Aug; 62(8):1933-1943. PubMed ID: 28523579
[TBL] [Abstract][Full Text] [Related]
18. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience.
Marshall AD; Grebely J; Dore GJ; Treloar C
Drug Alcohol Depend; 2020 Jan; 206():107705. PubMed ID: 31718924
[TBL] [Abstract][Full Text] [Related]
19. Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers.
Fontaine G; Presseau J; Bruneau J; Etherington C; Thomas IM; Hung JC; van Allen Z; Patey AM; Kareem A; Mortazhejri S; Høj SB; Boyer-Legault G; Grimshaw JM
Int J Equity Health; 2024 Jun; 23(1):124. PubMed ID: 38886803
[TBL] [Abstract][Full Text] [Related]
20. Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting.
Yela E; Solé N; Puig L; López Gallegos D; Clua-García R
Harm Reduct J; 2024 Apr; 21(1):88. PubMed ID: 38678266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
